

October 31, 2023

Company name	Nihon Chouzai Co., Ltd.
Company representative	Yosuke Mitsuhashi, President and CEO
Securities code	3341; Tokyo Stock Exchange Prime Market
Contacts	Kei Kato, General Manager of Corporate Planning Department (Phone: +81-3-6810-0800)

Notice of Difference Between Forecast and Actual Results for the First Half of FY2024 and Revision of Full-Year Earnings Forecast

Nihon Chouzai announces that there was a difference between the consolidated earnings forecast for the first half of the fiscal year ending March 31, 2024 (FY'24/3), which was released on April 28, 2023, and the actual results, and we have decided to revise the consolidated earnings forecast for the fiscal year ending March 31, 2024, based on these actual results, as follows.

1. Difference between Consolidated Forecast and Actual Results for the First Half of FY'24/3 (from April 1 to September 30, 2023)

	Sales	EBITDA	Operating Profit	Ordinary Profit	Profit Attributable to Owners of Parent	Net Income per Share
Previous Forecast (A)	¥ million 164,100	¥ million 5,700	¥ million 1,400	¥ million 1,400	¥ million 400	¥ 13.37
Actual Result (B)	166,310	7,573	3,397	3,367	1,748	58.44
Difference (B-A)	2,210	1,873	1,997	1,967	1,348	45.07
Difference (%)	1.3	32.9	142.7	140.5	337.0	—

2. Revision of Full-Year Forecast for FY3/2024 (from April 1, 2023 to March 31,2024)

	Sales	EBITDA	Operating Profit	Ordinary Profit	Profit Attributable to Owners of Parent	Net Income per Share
Previous Forecast (A)	¥ million 334,400	¥ million 15,300	¥ million 6,400	¥ million 6,300	¥ million 3,200	¥ 106.97
Actual Result (B)	337,100	17,300	8,400	8,300	4,300	143.74
Difference (B-A)	2,700	2,000	2,000	2,000	1,100	36.77
Difference (%)	0.8	13.1	31.3	31.7	34.4	—

3. Reason for the difference and Adjustment

Consolidated net sales and each profit for the first half of the fiscal year ending March 31, 2024 exceeded the previously announced forecasts due to favorable increase in the number of prescriptions in the dispensing pharmacy business, steady sales of existing products and new NHI-listed products in the pharmaceutical manufacturing and sales business, and an increase in staffing demand for pharmacists in the Medical Professional Staffing and Placement Business as well as the contribution of company-wide cost containment to business results.

For the full-year forecast for the fiscal year ending March 31, 2024, based on the results of the first half of the current fiscal year, we expect consolidated net sales and each profit to exceed the previous forecast as well, mainly due to the expected contribution from continued company-wide cost containment in the third quarter and beyond.

Please refer to the " Summary of Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2024" released today for the actual results for the first half of the fiscal year ending March 31, 2023.

Actual results may differ from these forecasts due to various factors in the future.

End